Highest-materiality recent filing
Eli Lilly to acquire Centessa for $38/share plus up to $9 in CVRs
Centessa shareholders receive $38.00 per share cash plus CVRs worth up to $9.00 per share on milestone achievement.
Centessa finalizes advisory and separation pacts with former CEO Saha
Saurabh Saha stepped down as CEO on Jan 1, 2026; advisory agreement signed Feb 9, 2026.
Centessa appoints Mario Accardi CEO effective Jan 1, 2026; base salary $600K, target bonus 50%
Employment Agreement signed Jan 5, 2026; base salary $600,000 per year.
Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026
Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.
Centessa Pharma enters into $250M ATM equity offering facility with Leerink Partners
Up to $250M of American Depositary Shares may be sold through Leerink as sales agent.
Centessa prices $250M public offering of 11.6M ADSs at $21.50 per ADS
Priced 11,627,907 ADSs at $21.50 each; gross proceeds ~$250M; net proceeds ~$234.4M.
Centessa reports Q3 net loss of $54.9M; ORX750 Phase 2a meets endpoints in NT1, NT2, IH
Net loss of $54.9M in Q3 2025 vs $42.6M in Q3 2024; R&D expenses rose to $41.6M.
Centessa Q2 net loss $50.3M; cash $404.1M; ORX750 Phase 2a data on track for 2025
Net loss of $50.3M for Q2 2025, up from $43.8M in Q2 2024; R&D expenses rose to $42.7M.
Centessa shareholders approve all proposals at 2025 AGM, including director re-elections
Re-elected Arjun Goyal with 116.9M votes for, 463,793 against; Samarth Kulkarni with 97.7M for, 19.6M against.
FDA clears IND for Centessa's ORX142, Phase 1 study in sleep-deprived volunteers planned
FDA cleared IND for ORX142, a novel OX2R agonist for neurological/neurodegenerative disorders.
Centessa appoints Raphael Deferiere as Chief Accounting Officer
Raphael Deferiere, CPA, appointed CAO effective May 27, 2025; John Crowley remains CFO.
Mr. Deferiere assumes the designation of principal accounting officer from John Crowley, who continues in his capacity as Chief Financial Officer and the Company’s principal financial officer.
On May 27, 2025, Centessa Pharmaceuticals plc (the “Company”) appointed Raphael Deferiere, CPA, as the Company’s Chief Accounting Officer and designated him as the Company’s principal accounting officer, each effective as of May 27, 2025.
Max materiality 0.95 · Median 0.60 · Most common event leadership